NCT04789681 - Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Lung CarcinomaStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8

Interventions

DRUG

Canakinumab

Given SC

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER